Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Re Lamoureux is active.

Publication


Featured researches published by Re Lamoureux.


Breast Cancer: Basic and Clinical Research | 2016

Patient-Reported Outcomes in Metastatic Breast Cancer: A Review of Industry-Sponsored Clinical Trials

Meaghan Krohe; Yanni Hao; Re Lamoureux; Nina Galipeau; Catherine Foley; Iyar Mazar; Jeffrey Solomon; Alan L. Shields

Introduction Patient-reported outcome (PRO) measures serve to capture vital patient information not otherwise obtained by primary study endpoints. This paper examines how PROs are utilized as endpoints in industry-sponsored metastatic breast cancer clinical trials. Methods A search was conducted in the clinicaltrials.gov web site for trials involving common treatments for metastatic breast cancer. Thirty-eight clinical trials were identified which included a PRO endpoint in the study, and data were extracted and summarized. Results Overall, 17 unique PRO questionnaires and 14 concepts of measurement were identified as secondary or exploratory endpoints. The Functional Assessment of Cancer Therapy—Breast was the most frequently utilized questionnaire, commonly implemented to assess quality of life. The EORTC QLQ-C30 was also frequently used to measure quality of life or pain. Conclusion This review shares insights into the role of PROs in trials for metastatic breast cancer from which treatment developers and other stakeholders can enhance successful implementation of the patient voice into future trials.


Value in Health | 2018

Informing a priori Sample Size Estimation in Qualitative Concept Elicitation Interview Studies for Clinical Outcome Assessment (COA) Instrument Development

Diane M. Turner-Bowker; Re Lamoureux; J. Stokes; Leighann Litcher-Kelly; Nina Galipeau; Andrew Yaworsky; Jeffrey Solomon; Alan L. Shields

OBJECTIVE Evidence-based recommendations for the a priori estimation of sample size are needed for qualitative concept elicitation (CE) interview studies in clinical outcome assessment (COA) instrument development. Saturation is described as the point at which no new data is expected to emerge from the conduct of additional qualitative interviews. STUDY DESIGN A retrospective evaluation of 26 CE interview studies conducted with patients between 2006 and 2013 was completed to assess the point at which saturation of concept was achieved in each study. METHODS For each of the 26 interview studies, saturation of symptom concepts was assessed by dividing the sample into quartiles and then comparing the number of responses elicited from the first 25% of participants to the next 25% of participants, from the first 50% of participants to the next 25% of participants, and then from the first 75% of participants to the last 25% of participants. The number of interviews required to achieve saturation was documented for each study and then summarized across studies. RESULTS Findings indicate that 84% of symptom concepts emerged by the 10th interview, 92% emerged by the 15th interview, 97% emerged by the 20th interview, and 99% by the 25th interview. CONCLUSIONS Results provide practical guidance for estimating the number of interviews that may be needed to achieve saturation in a qualitative CE interview study for COA instrument development; address an important gap in qualitative research for the development of COAs in the context of medical product development; and offer useful information for study design and implementation.


Value in Health | 2015

How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies

Re Lamoureux; Alan L. Shields; J. Stokes; Andrew Yaworsky; Nina Galipeau


Value in Health | 2018

Psychometric Evaluation of Questionnaires Assessing Injection Regimen Burden in Growth Hormone Deficient (GHD) Adults and Children Treated with Growth Hormone

Diane M. Turner-Bowker; Andrew Yaworsky; A Palladino; Andreas M. Pleil; Alan L. Shields; M Kelly; Re Lamoureux; E Love; L Morrissey; Jane Loftus


Diabetes | 2018

Exploring the Type 2 Diabetes Mellitus Experience from the Patient Perspective

Kristina Yu-Isenberg; Geof D. Gray; Catherine Foley; J. Stokes; Alan L. Shields; Gavin Dickie; Re Lamoureux; Clark V. Jackson; Brad Padilla; William H. Polonsky


Diabetes | 2018

Patient Perspectives on the Burden of Type 2 Diabetes Mellitus Treatment

Kristina Yu-Isenberg; Geof D. Gray; Catherine Foley; J. Stokes; Alan L. Shields; Gavin Dickie; Re Lamoureux; Clark V. Jackson; Brad Padilla; William H. Polonsky


Value in Health | 2017

Cognitive Debriefing Of The Advanced Systemic Mastocytosis Symptom Assessment Form (ADVSM-SAF)

Fiona Taylor; S. Kreil; A. Reiter; H. Horny; E. Evans; Iyar Mazar; P. McNamara; A. Boral; Re Lamoureux; Alan L. Shields; J. Gotlib


Value in Health | 2017

Caregiver Burden In Daily Human Growth Hormone Injections For Children

Jane Loftus; Re Lamoureux; Andrew Yaworsky; Alan L. Shields; L Morrissey; M Kelly; E Love; Andreas M. Pleil; G Hart; O Hershkovitz; Diane M. Turner-Bowker


Value in Health | 2017

Agreement Between Patient And Clinician Ratings Of Disease Severity In Hidradenitis Suppurativa, Rheumatoid Arthritis, And Chronic Plaque Psoriasis

Catherine Foley; Benjamin Banderas; R Sen; C Yip; G Dickie; Re Lamoureux


Value in Health | 2016

Development and Content Validity of the Advanced Systemic Mastocytosis Symptom Assessment Form (ADVSM-SAF)

Mazar; E. Evans; Fiona Taylor; A Patki; O Ojo; Re Lamoureux; H. Horny; A. Reiter; J. Gotlib; Alan L. Shields

Collaboration


Dive into the Re Lamoureux's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge